# Mycobacterial antigen Ag85B restrains Hodgkin lymphoma tumor growth by inhibiting autophagy

**Authors:** YONGFENG CHENG, YIPING SHEN, YUNFEI ZHANG, HAILIQIGULI NURIDING, XUEMEI WANG, CHUNYAN FAN, GULIBAHA MAIMAITI, YU LIU, YINGBIN YUE, DANLU LI, MEI YAN

PMC · DOI: 10.32604/or.2025.057842 · Oncology Research · 2025-04-18

## TL;DR

This study shows that the mycobacterial antigen Ag85B can slow the growth of Hodgkin lymphoma by inhibiting autophagy and promoting cell death.

## Contribution

The study is the first to demonstrate that Ag85B inhibits autophagy and tumor growth in Hodgkin lymphoma.

## Key findings

- Ag85B treatment reduced autophagy and proliferation in Hodgkin lymphoma cells.
- Ag85B induced apoptosis in HL cells, possibly through mitochondrial dysfunction.
- Ag85B inhibited lymphoma growth in mice without observed toxicity.

## Abstract

The growth of the B-cell lymphoma subtype, Hodgkin lymphoma (HL), is associated with increased autophagy. A mycobacterial antigen, Ag85, has been reported to inhibit cell autophagy under a variety of conditions. Whether Ag85 could inhibit autophagy in HL is unknown.

Lymph node samples from patients with HL and healthy controls were collected to assess proliferation and autophagy. The human HL cell line, L-428, was cultured and subjected to Ag85B treatment. Autophagy in L-428 cells was evaluated through western blotting analysis, immunohistochemistry, and transmission electron microscopy. Apoptosis in these cells was measured using flow cytometry and western blotting. The associated signaling pathways were also analyzed utilizing western blotting. The in vivo impact of Ag85B was studied using BALB/c Nude mice xenografted with L-428 cells.

We observed increased proliferation and autophagy in primary lymphoma tissues of patients. Administration of Ag85B inhibited the proliferation and autophagy of HL cell lines. Moreover, Ag85B promoted apoptotic pathway activation in vitro, which might be associated with mitochondrial dysfunction. Mechanistically, Ag85B inhibits autophagy by activating the phosphatidylinositol-4,5-bisphosphate 3-kinase/protein kinase B/mechanistic target of rapamycin kinase (PI3K/AKT/mTOR) and mitogen-activated protein kinase (MAPK) pathways. Ag85B also inhibited lymphoma growth in mice xenografted with HL cell lines, but no potential toxicity was observed.

Altogether, these results suggest that Ag85B inhibits HL growth via autophagy regulation. Current treatments for HL are associated with adverse events; therefore, Ag85B-mediated autophagy inhibition might be a promising strategy in to treat HL.

## Linked entities

- **Proteins:** ag85B (diacylglycerol acyltransferase/mycolyltransferase Ag85B), MPK1 (mitogen-activated protein kinase 1)
- **Diseases:** Hodgkin lymphoma (MONDO:0004952)
- **Species:** Homo sapiens (taxon 9606), Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, PTK2B (protein tyrosine kinase 2 beta) [NCBI Gene 2185] {aka CADTK, CAKB, FADK2, FAK2, PKB, PTK}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}
- **Diseases:** B-cell lymphoma (MESH:D016393), toxicity (MESH:D064420), lymphoma (MESH:D008223), HL (MESH:D006689), mitochondrial dysfunction (MESH:D028361)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** L-428 — Homo sapiens (Human), Hodgkin lymphoma, Cancer cell line (CVCL_1361)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12034006/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12034006/full.md

## References

55 references — full list in the complete paper: https://tomesphere.com/paper/PMC12034006/full.md

---
Source: https://tomesphere.com/paper/PMC12034006